On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 13, 2023 at 10:52: AM
via Corbus Pharmaceuticals is mounting a David vs. Goliath battle against Seagen, spending $7.5 million of its dwindling cash reserves on a challenger to the nectin-4 antibody-drug conjugate (ADC) Padcev.

article source
 

<



Similar threads

cafead
Walgreens Turns $344 Million Profit As CEO Asks Patience On Turnaround
Replies
0
Views
7
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Joseph Papa, after leaving Bausch, begins another turnaround project as CEO of Emergent...
Replies
0
Views
101
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pharvaris&#039; oral hereditary angioedema med slashes attacks in turnaround post-FDA hold
Replies
0
Views
126
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Replies
0
Views
82
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Arena, completing its turnaround, sells to Pfizer for nearly $7 billion
Replies
0
Views
294
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote